43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Titel:
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Auteur:
Leal, T.A. Berz, D. Rybkin, I. Iams, W.T. Bruno, D. Blakely, C. Spira, A. Patel, M. Waterhouse, D.M. Richards, D. Pham, A. Jotte, R. Garon, E.B. Hong, D.S. Shazer, R. Yan, X. Latven, L. He, K.